Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2021

Open Access 01-12-2021 | Liver Resection | Research

The impact of thrombocytopenia on prognosis of HBV-related small hepatocellular carcinoma: a propensity score matching analysis

Authors: Wei Peng, Chuan Li, Xiaoyun Zhang, Tianfu Wen, Zheyu Chen

Published in: World Journal of Surgical Oncology | Issue 1/2021

Login to get access

Abstract

Background

Thrombocytopenia was reported both detrimental and advantageous to hepatocellular carcinoma (HCC). However, there is little evidence showing clearly the clinical value of preoperative thrombocytopenia on the surgical outcome of patients with small HCC. This retrospective study aimed at elucidating the correlation between preoperative thrombocytopenia and surgical outcome of small HCC patients within Milan criteria treated with liver resection.

Methods

Data of hepatitis B virus (HBV)-related small HCC patients were retrospectively analyzed, and we performed the propensity score matching (PSM) analysis to overcome the imbalance of clinicopathological features. Patients enrolled were subsequently categorized into two groups according to preoperative platelet counts: thrombocytopenia group and non-thrombocytopenia group. Survival outcomes of the patients in both groups were described with the Kaplan-Meier method, and the difference was compared with a log-rank test. Cox regression analysis was applied to identify the risk factors of surgical outcome.

Results

After PSM, the estimated 1-, 3-, and 5-year overall survival (OS) rates for small HCC patients in the thrombocytopenia group were 94.5%, 77.0%, and 57.6%, and 95.0%, 79.6%, and 68.0%, respectively, for small HCC patients in the non-thrombocytopenia group (P = 0.042). And the 1-, 3-, and 5-year estimated recurrence-free survival (RFS) rates for small HCC patients in the thrombocytopenia group were 70.4%, 51.0%, and 42.1%, and 83.8%, 63.7%, and 46.7%, respectively, for small HCC patients in the non-thrombocytopenia group (P = 0.035). Multivariate analysis indicated preoperative thrombocytopenia was a significant prognosticator of poor RFS (hazard ratio (HR) = 1.388, 95% confidence interval (CI) 1.028~1.874, P = 0.033).

Conclusion

Preoperative thrombocytopenia had an undesirable impact on the recurrence of small HCC patients treated with liver resection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRef Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRef
2.
go back to reference Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond). 2019;39:22.CrossRef Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond). 2019;39:22.CrossRef
3.
go back to reference Zheng J, Chou JF, Gonen M, et al. Prediction of hepatocellular carcinoma recurrence beyond Milan criteria after resection: validation of a clinical risk score in an international cohort. Ann Surg. 2017;266:693–701.CrossRef Zheng J, Chou JF, Gonen M, et al. Prediction of hepatocellular carcinoma recurrence beyond Milan criteria after resection: validation of a clinical risk score in an international cohort. Ann Surg. 2017;266:693–701.CrossRef
4.
go back to reference Chapman WC, Klintmalm G, Hemming A, et al. Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified? J Am Coll Surg. 2015;220:628–37.CrossRef Chapman WC, Klintmalm G, Hemming A, et al. Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified? J Am Coll Surg. 2015;220:628–37.CrossRef
5.
go back to reference Poon RT, Fan ST, Lo CM, et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235:373–82.CrossRef Poon RT, Fan ST, Lo CM, et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235:373–82.CrossRef
6.
go back to reference Chauhan A, Adams DH, Watson SP, Lalor PF. Platelets: no longer bystanders in liver disease. Hepatology. 2016;64:1774–84.CrossRef Chauhan A, Adams DH, Watson SP, Lalor PF. Platelets: no longer bystanders in liver disease. Hepatology. 2016;64:1774–84.CrossRef
7.
go back to reference Philippe C, Philippe B, Fouqueray B, et al. Protection from tumor necrosis factor-mediated cytolysis by platelets. Am J Pathol. 1993;143:1713–23.PubMedPubMedCentral Philippe C, Philippe B, Fouqueray B, et al. Protection from tumor necrosis factor-mediated cytolysis by platelets. Am J Pathol. 1993;143:1713–23.PubMedPubMedCentral
8.
go back to reference Wang YH, Kang JK, Zhi YF, et al. The pretreatment thrombocytosis as one of prognostic factors for gastric cancer: a systematic review and meta-analysis. Int J Surg. 2018;53:304–11.CrossRef Wang YH, Kang JK, Zhi YF, et al. The pretreatment thrombocytosis as one of prognostic factors for gastric cancer: a systematic review and meta-analysis. Int J Surg. 2018;53:304–11.CrossRef
9.
go back to reference Gu D, Szallasi A. Thrombocytosis portends adverse prognosis in colorectal cancer: a meta-analysis of 5,619 patients in 16 individual studies. Anticancer Res. 2017;37:4717–26.PubMed Gu D, Szallasi A. Thrombocytosis portends adverse prognosis in colorectal cancer: a meta-analysis of 5,619 patients in 16 individual studies. Anticancer Res. 2017;37:4717–26.PubMed
10.
go back to reference Lee M, Chung GE, Lee JH, et al. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology. 2017;66:1556–69.CrossRef Lee M, Chung GE, Lee JH, et al. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology. 2017;66:1556–69.CrossRef
11.
go back to reference Lee PC, Yeh CM, Hu YW, et al. Antiplatelet therapy is associated with a better prognosis for patients with hepatitis B virus-related hepatocellular carcinoma after liver resection. Ann Surg Oncol. 2016;23:874–83.CrossRef Lee PC, Yeh CM, Hu YW, et al. Antiplatelet therapy is associated with a better prognosis for patients with hepatitis B virus-related hepatocellular carcinoma after liver resection. Ann Surg Oncol. 2016;23:874–83.CrossRef
12.
go back to reference Lee TY, Hsu YC, Tseng HC et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B. JAMA Intern Med 2019. Lee TY, Hsu YC, Tseng HC et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B. JAMA Intern Med 2019.
13.
go back to reference Mehrabi A, Golriz M, Khajeh E, et al. Meta-analysis of the prognostic role of perioperative platelet count in posthepatectomy liver failure and mortality. Br J Surg. 2018;105:1254–61.CrossRef Mehrabi A, Golriz M, Khajeh E, et al. Meta-analysis of the prognostic role of perioperative platelet count in posthepatectomy liver failure and mortality. Br J Surg. 2018;105:1254–61.CrossRef
14.
go back to reference Amano H, Tashiro H, Oshita A, et al. Significance of platelet count in the outcomes of hepatectomized patients with hepatocellular carcinoma exceeding the Milan criteria. J Gastrointest Surg. 2011;15:1173–81.CrossRef Amano H, Tashiro H, Oshita A, et al. Significance of platelet count in the outcomes of hepatectomized patients with hepatocellular carcinoma exceeding the Milan criteria. J Gastrointest Surg. 2011;15:1173–81.CrossRef
15.
go back to reference Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer ≤ 2 cm: results from two Western centers. Hepatology. 2013;57:1426–35.CrossRef Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer ≤ 2 cm: results from two Western centers. Hepatology. 2013;57:1426–35.CrossRef
16.
go back to reference Wu WC, Chiou YY, Hung HH, et al. Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation. J Clin Gastroenterol. 2012;46:789–95.CrossRef Wu WC, Chiou YY, Hung HH, et al. Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation. J Clin Gastroenterol. 2012;46:789–95.CrossRef
17.
go back to reference Kao WY, Chiou YY, Hung HH, et al. Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy. J Clin Gastroenterol. 2012;46:62–70.CrossRef Kao WY, Chiou YY, Hung HH, et al. Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy. J Clin Gastroenterol. 2012;46:62–70.CrossRef
18.
go back to reference Bihari C, Rastogi A, Shasthry SM, et al. Platelets contribute to growth and metastasis in hepatocellular carcinoma. Apmis. 2016;124:776–86.CrossRef Bihari C, Rastogi A, Shasthry SM, et al. Platelets contribute to growth and metastasis in hepatocellular carcinoma. Apmis. 2016;124:776–86.CrossRef
19.
go back to reference Morimoto Y, Nouso K, Wada N, et al. Involvement of platelets in extrahepatic metastasis of hepatocellular carcinoma. Hepatol Res. 2014;44:E353–9.CrossRef Morimoto Y, Nouso K, Wada N, et al. Involvement of platelets in extrahepatic metastasis of hepatocellular carcinoma. Hepatol Res. 2014;44:E353–9.CrossRef
20.
go back to reference Cheng YQ, Wang K, Zhang XP, et al. Thrombocytopenia: a prognostic factor for hepatocellular carcinoma patients with portal vein tumor thrombus after hepatectomy. J Gastroenterol Hepatol. 2018. Cheng YQ, Wang K, Zhang XP, et al. Thrombocytopenia: a prognostic factor for hepatocellular carcinoma patients with portal vein tumor thrombus after hepatectomy. J Gastroenterol Hepatol. 2018.
21.
go back to reference Scheiner B, Kirstein M, Popp S, et al. Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma. Liver Cancer. 2019;8:203–17.CrossRef Scheiner B, Kirstein M, Popp S, et al. Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma. Liver Cancer. 2019;8:203–17.CrossRef
22.
go back to reference Hayashi H, Beppu T, Shirabe K, et al. Management of thrombocytopenia due to liver cirrhosis: a review. World J Gastroenterol. 2014;20:2595–605.CrossRef Hayashi H, Beppu T, Shirabe K, et al. Management of thrombocytopenia due to liver cirrhosis: a review. World J Gastroenterol. 2014;20:2595–605.CrossRef
23.
go back to reference Wen T, Jin C, Facciorusso A, et al. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr. 2018;7:353–71.CrossRef Wen T, Jin C, Facciorusso A, et al. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr. 2018;7:353–71.CrossRef
24.
go back to reference Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98:2720–5.CrossRef Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98:2720–5.CrossRef
25.
go back to reference Iannacone M, Sitia G, Narvaiza I, et al. Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus. Clin Vaccine Immunol. 2007;14:1532–5.CrossRef Iannacone M, Sitia G, Narvaiza I, et al. Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus. Clin Vaccine Immunol. 2007;14:1532–5.CrossRef
26.
go back to reference Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105:178–85.CrossRef Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105:178–85.CrossRef
27.
go back to reference Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126:582–8.CrossRef Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126:582–8.CrossRef
28.
go back to reference Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48:1000–7.CrossRef Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48:1000–7.CrossRef
29.
go back to reference Giannini E, Botta F, Borro P, et al. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. Am J Gastroenterol. 2003;98:2516–20.CrossRef Giannini E, Botta F, Borro P, et al. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. Am J Gastroenterol. 2003;98:2516–20.CrossRef
30.
go back to reference Kang CM, Choi GH, Kim DH, et al. Revisiting the role of nonanatomic resection of small (< or = 4 cm) and single hepatocellular carcinoma in patients with well-preserved liver function. J Surg Res. 2010;160:81–9.CrossRef Kang CM, Choi GH, Kim DH, et al. Revisiting the role of nonanatomic resection of small (< or = 4 cm) and single hepatocellular carcinoma in patients with well-preserved liver function. J Surg Res. 2010;160:81–9.CrossRef
31.
go back to reference Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749–61.CrossRef Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749–61.CrossRef
32.
go back to reference Poon RTP, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinorna. Annals of Surgery. 2000;232:10–24.CrossRef Poon RTP, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinorna. Annals of Surgery. 2000;232:10–24.CrossRef
33.
go back to reference Kubo S, Tanaka H, Shuto T, et al. Correlation between low platelet count and multicentricity of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatol Res. 2004;30:221–5.CrossRef Kubo S, Tanaka H, Shuto T, et al. Correlation between low platelet count and multicentricity of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatol Res. 2004;30:221–5.CrossRef
34.
go back to reference Nouso K, Matsumoto E, Kobayashi Y, et al. Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. J Gastroenterol Hepatol. 2008;23:453–8.CrossRef Nouso K, Matsumoto E, Kobayashi Y, et al. Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. J Gastroenterol Hepatol. 2008;23:453–8.CrossRef
35.
go back to reference Xue TC, Ge NL, Xu X, et al. High platelet counts increase metastatic risk in huge hepatocellular carcinoma undergoing transarterial chemoembolization. Hepatol Res. 2016;46:1028–36.CrossRef Xue TC, Ge NL, Xu X, et al. High platelet counts increase metastatic risk in huge hepatocellular carcinoma undergoing transarterial chemoembolization. Hepatol Res. 2016;46:1028–36.CrossRef
36.
go back to reference Tao Y, Li Y, Liu X, et al. Nonsteroidal anti-inflammatory drugs, especially aspirin, are linked to lower risk and better survival of hepatocellular carcinoma: a meta-analysis. Cancer Manag Res. 2018;10:2695–709.CrossRef Tao Y, Li Y, Liu X, et al. Nonsteroidal anti-inflammatory drugs, especially aspirin, are linked to lower risk and better survival of hepatocellular carcinoma: a meta-analysis. Cancer Manag Res. 2018;10:2695–709.CrossRef
37.
go back to reference Jankowska H, Hooper P, Jankowski JA. Aspirin chemoprevention of gastrointestinal cancer in the next decade. A review of the evidence. Pol Arch Med Wewn. 2010;120:407–12.PubMed Jankowska H, Hooper P, Jankowski JA. Aspirin chemoprevention of gastrointestinal cancer in the next decade. A review of the evidence. Pol Arch Med Wewn. 2010;120:407–12.PubMed
38.
go back to reference Leng J, Han C, Demetris AJ, et al. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology. 2003;38:756–68.CrossRef Leng J, Han C, Demetris AJ, et al. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology. 2003;38:756–68.CrossRef
39.
go back to reference Kurokawa T, Ohkohchi N. Platelets in liver disease, cancer and regeneration. World J Gastroenterol. 2017;23:3228–39.CrossRef Kurokawa T, Ohkohchi N. Platelets in liver disease, cancer and regeneration. World J Gastroenterol. 2017;23:3228–39.CrossRef
Metadata
Title
The impact of thrombocytopenia on prognosis of HBV-related small hepatocellular carcinoma: a propensity score matching analysis
Authors
Wei Peng
Chuan Li
Xiaoyun Zhang
Tianfu Wen
Zheyu Chen
Publication date
01-12-2021
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2021
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-021-02160-2

Other articles of this Issue 1/2021

World Journal of Surgical Oncology 1/2021 Go to the issue